ID   ANKK1_HUMAN             Reviewed;         765 AA.
AC   Q8NFD2;
DT   24-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   02-NOV-2010, entry version 68.
DE   RecName: Full=Ankyrin repeat and protein kinase domain-containing protein 1;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase PKK2;
DE   AltName: Full=Sugen kinase 288;
DE            Short=SgK288;
DE   AltName: Full=X-kinase;
GN   Name=ANKK1; Synonyms=PKK2, SGK288;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=15146457; DOI=10.1002/humu.20039;
RA   Neville M.J., Johnstone E.C., Walton R.T.;
RT   "Identification and characterization of ANKK1: a novel kinase gene
RT   closely linked to DRD2 on chromosome band 11q23.1.";
RL   Hum. Mutat. 23:540-545(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Inohara N.;
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND VARIANT
RP   LYS-713.
RX   PubMed=14741327; DOI=10.1016/S0920-9964(03)00220-2;
RA   Dubertret C., Gouya L., Hanoun N., Deybach J.-C., Ades J., Hamon M.,
RA   Gorwood P.;
RT   "The 3' region of the DRD2 gene is involved in genetic susceptibility
RT   to schizophrenia.";
RL   Schizophr. Res. 67:75-85(2004).
RN   [4]
RP   IDENTIFICATION.
RX   PubMed=12471243; DOI=10.1126/science.1075762;
RA   Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S.;
RT   "The protein kinase complement of the human genome.";
RL   Science 298:1912-1934(2002).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-694, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
RN   [6]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-4; HIS-122; THR-239; LEU-276;
RP   ARG-318; THR-347; PHE-366; GLN-367; LYS-376; LYS-426; ARG-442;
RP   ARG-451; ARG-490; ILE-595; LEU-596; SER-653; GLY-670; LYS-713;
RP   LEU-717; LEU-736 AND LYS-764.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain and weakly expressed
CC       in placenta and spinal cord.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family.
CC   -!- SIMILARITY: Contains 12 ANK repeats.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ541797; CAD62569.2; -; mRNA.
DR   EMBL; AF487542; AAQ09005.1; -; mRNA.
DR   EMBL; AF525298; AAM91924.1; -; Genomic_DNA.
DR   IPI; IPI00168819; -.
DR   RefSeq; NP_848605.1; -.
DR   UniGene; Hs.448473; -.
DR   ProteinModelPortal; Q8NFD2; -.
DR   SMR; Q8NFD2; 27-282, 363-747.
DR   STRING; Q8NFD2; -.
DR   PhosphoSite; Q8NFD2; -.
DR   PRIDE; Q8NFD2; -.
DR   Ensembl; ENST00000303941; ENSP00000306678; ENSG00000170209.
DR   GeneID; 255239; -.
DR   KEGG; hsa:255239; -.
DR   UCSC; uc001pny.1; human.
DR   CTD; 255239; -.
DR   GeneCards; GC11P113292; -.
DR   H-InvDB; HIX0035904; -.
DR   HGNC; HGNC:21027; ANKK1.
DR   HPA; HPA012813; -.
DR   MIM; 608774; gene.
DR   PharmGKB; PA134872551; -.
DR   eggNOG; prNOG07630; -.
DR   HOGENOM; HBG444289; -.
DR   HOVERGEN; HBG061582; -.
DR   InParanoid; Q8NFD2; -.
DR   OMA; KRPCFPD; -.
DR   OrthoDB; EOG9DFS80; -.
DR   BRENDA; 2.7.11.1; 247.
DR   NextBio; 92527; -.
DR   ArrayExpress; Q8NFD2; -.
DR   Bgee; Q8NFD2; -.
DR   CleanEx; HS_ANKK1; -.
DR   Genevestigator; Q8NFD2; -.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   Gene3D; G3DSA:1.25.40.20; ANK; 4.
DR   Pfam; PF00023; Ank; 10.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   SMART; SM00248; ANK; 11.
DR   SUPFAM; SSF48403; ANK; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 11.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   ANK repeat; ATP-binding; Complete proteome; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Repeat;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    765       Ankyrin repeat and protein kinase domain-
FT                                containing protein 1.
FT                                /FTId=PRO_0000085620.
FT   DOMAIN       22    289       Protein kinase.
FT   REPEAT      361    390       ANK 1.
FT   REPEAT      394    423       ANK 2.
FT   REPEAT      427    456       ANK 3.
FT   REPEAT      460    489       ANK 4.
FT   REPEAT      493    522       ANK 5.
FT   REPEAT      526    555       ANK 6.
FT   REPEAT      559    588       ANK 7.
FT   REPEAT      592    621       ANK 8.
FT   REPEAT      625    654       ANK 9.
FT   REPEAT      658    687       ANK 10.
FT   REPEAT      691    720       ANK 11.
FT   REPEAT      724    753       ANK 12.
FT   NP_BIND      28     36       ATP (By similarity).
FT   ACT_SITE    145    145       Proton acceptor (By similarity).
FT   BINDING      51     51       ATP (By similarity).
FT   MOD_RES     694    694       Phosphothreonine.
FT   VARIANT       4      4       D -> Y (in dbSNP:rs35657708).
FT                                /FTId=VAR_040359.
FT   VARIANT     122    122       R -> H (in dbSNP:rs35877321).
FT                                /FTId=VAR_040360.
FT   VARIANT     239    239       A -> T (in dbSNP:rs7118900).
FT                                /FTId=VAR_036784.
FT   VARIANT     276    276       P -> L (in dbSNP:rs35488601).
FT                                /FTId=VAR_040361.
FT   VARIANT     318    318       G -> R (in dbSNP:rs11604671).
FT                                /FTId=VAR_036785.
FT   VARIANT     347    347       K -> T (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040362.
FT   VARIANT     366    366       L -> F (in dbSNP:rs56339158).
FT                                /FTId=VAR_040363.
FT   VARIANT     367    367       H -> Q (in dbSNP:rs34298987).
FT                                /FTId=VAR_040364.
FT   VARIANT     376    376       E -> K (in dbSNP:rs56299709).
FT                                /FTId=VAR_040365.
FT   VARIANT     426    426       E -> K (in dbSNP:rs55699907).
FT                                /FTId=VAR_040366.
FT   VARIANT     442    442       G -> R (in dbSNP:rs4938016).
FT                                /FTId=VAR_036786.
FT   VARIANT     451    451       G -> R (in dbSNP:rs34983219).
FT                                /FTId=VAR_040367.
FT   VARIANT     490    490       H -> R (in dbSNP:rs2734849).
FT                                /FTId=VAR_036787.
FT   VARIANT     595    595       T -> I (in dbSNP:rs55787008).
FT                                /FTId=VAR_040368.
FT   VARIANT     596    596       P -> L (in dbSNP:rs7104979).
FT                                /FTId=VAR_040369.
FT   VARIANT     653    653       N -> S (in dbSNP:rs55849504).
FT                                /FTId=VAR_040370.
FT   VARIANT     670    670       S -> G (in dbSNP:rs56006094).
FT                                /FTId=VAR_040371.
FT   VARIANT     713    713       E -> K (in dbSNP:rs1800497).
FT                                /FTId=VAR_025010.
FT   VARIANT     717    717       Q -> L (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040372.
FT   VARIANT     736    736       R -> L (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040373.
FT   VARIANT     764    764       E -> K (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040374.
SQ   SEQUENCE   765 AA;  84632 MW;  549F6161B2976BF5 CRC64;
     MAADPTELRL GSLPVFTRDD FEGDWRLVAS GGFSQVFQAR HRRWRTEYAI KCAPCLPPDA
     ASSDVNYLIE EAAKMKKIKF QHIVSIYGVC KQPLGIVMEF MANGSLEKVL STHSLCWKLR
     FRIIHETSLA MNFLHSIKPP LLHLDLKPGN ILLDSNMHVK ISDFGLSKWM EQSTRMQYIE
     RSALRGMLSY IPPEMFLESN KAPGPKYDVY SFAIVIWELL TQKKPYSGFN MMMIIIRVAA
     GMRPSLQPVS DQWPSEAQQM VDLMKRCWDQ DPKKRPCFLD ITIETDILLS LLQSRVAVPE
     SKALARKVSC KLSLRQPGEV NEDISQELMD SDSGNYLKRA LQLSDRKNLV PRDEELCIYE
     NKVTPLHFLV AQGSVEQVRL LLAHEVDVDC QTASGYTPLL IAAQDQQPDL CALLLAHGAD
     ANRVDEDGWA PLHFAAQNGD DGTARLLLDH GACVDAQERE GWTPLHLAAQ NNFENVARLL
     VSRQADPNLH EAEGKTPLHV AAYFGHVSLV KLLTSQGAEL DAQQRNLRTP LHLAVERGKV
     RAIQHLLKSG AVPDALDQSG YGPLHTAAAR GKYLICKMLL RYGASLELPT HQGWTPLHLA
     AYKGHLEIIH LLAESHANMG ALGAVNWTPL HLAARHGEEA VVSALLQCGA DPNAAEQSGW
     TPLHLAVQRS TFLSVINLLE HHANVHARNK VGWTPAHLAA LKGNTAILKV LVEAGAQLDV
     QDGVSCTPLQ LALRSRKQGI MSFLEGKEPS VATLGGSKPG AEMEI
//
